Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial

Qiao, YL; Wu, T; Li, RC; Hu, YM; Wei, LH; Li, CG; Chen, W; Huang, SJ; Zhao, FH; Li, MQ; Pan, QJ; Zhang, X; Li, Q; Hong, Y; Zhao, C; Zhang, WH; Li, YP; Chu, K; Li, M; Jiang, YF; Li, J; Zhao, H; Lin, ZJ; Cui, XL; Liu, WY; Li, CH; Guo, DP; Ke, LD; Wu, X; Tang, J; Gao, GQ; Li, BY; Zhao, B; Zheng, FX; Dai, CH; Guo, M; Zhao, J; Su, YY; Wang, JZ; Zhu, FC; Li, SW; Pan, HR; Li, YM; Zhang, J; Xia, NS

Zhang, J (corresponding author), Xiamen Univ, Sch Publ Hlth, State Key Lab Mol Vaccinol & Mol Diagnost, Xiangan South Rd, Xiamen 361102, Peoples R China.; Qiao, YL (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, 17 South Panjiayuan Lane, Beijing 100021, Peoples R China.; Xia, NS (corresponding author), Xiamen Univ, Sch Publ Hlth, Natl Inst Diagnost & Vaccine Dev Infect Dis, Xiangan South Rd, Xiamen 361102, Peoples R China.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2020; 112 (2): 145

Abstract

Background: The high cost and insufficient supply of human papillomavirus (HPV) vaccines have slowed the pace of controlling cervical cancer. A phase ......

Full Text Link